English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background The primary objective of our current HIV vaccine research program is to develop and evaluate novel recombinant alphavirus replicon and Env protein-based vaccine formulations against HIV that may offer improved immunogenicity and protective efficacy over other HIV vaccine approaches tested. Our approach described here is to employ diverse HIV Env antigens from transmitted HIV strains as substrates for the development of vaccine immunogens with enhanced exposure to the immune system of the conserved epitopes involved in virus binding/ entry. Previously, we showed that full protection of macaques from mucosal homologous SHIV challenge was achieved using recombinant VEE/SIN alphavirus Env prime Env protein boost. The aim of the present work is to build upon this work to identify novel Env immunogens.

P19-14. Recombinant alphavirus replicon particles as a platform to evaluate immunogenicity of early transmitted clade C virus envelopes